DOCSLIB.ORG

Environmental Health Criteria 18 ARSENIC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Environmental Health Criteria 18 ARSENIC Environmental Health Criteria 18 ARSENIC Please note that the layout and pagination of this web version are not identical with the printed version. Arsenic (EHC 18, 1981) IPCS INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY ENVIRONMENTAL HEALTH CRITERIA 18 ARSENIC This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organization, or the World Health Organization. Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization World Health Organization Geneva, 1981 ISBN 92 4 154078 8 (c) World Health Organization 1981 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or in toto, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. Page 1 of 149 Arsenic (EHC 18, 1981) CONTENTS ENVIRONMENTAL HEALTH CRITERIA FOR ARSENIC 1. SUMMARY AND RECOMMENDATIONS FOR FURTHER RESEARCH 1.1. Summary 1.1.1. Properties, uses, and analytical procedures 1.1.1.1 Properties and uses 1.1.1.2 Analytical procedures 1.1.2. Environmental transport and distribution 1.1.3. Exposure 1.1.4. Metabolism 1.1.5. Normal levels in man and biological indicators of exposure 1.1.6. Effects and evaluation of health risks 1.1.6.1 Inorganic arsenic compounds 1.1.6.2 Organic arsenic compounds 1.2. Recommendations for further research 1.2.1. Sampling and determination 1.2.2. Exposure 1.2.3. Metabolism and indicators of exposure 1.2.4. Effects 2. PROPERTIES AND ANALYTICAL PROCEDURES 2.1. Chemical and physical properties of arsenic compounds 2.1.1. Inorganic arsenic compounds 2.1.2. Organic arsenic compounds 2.2. Analytical procedures 2.2.1. Sampling and sample treatment 2.2.1.1 Natural waters 2.2.1.2 Air 2.2.1.3 Biological materials 2.2.2. Analytical methods 2.2.2.1 Methods for total arsenic 2.2.2.2 Analyses for specific arsenic compounds 3. SOURCES AND OCCURRENCE OF ARSENIC IN THE ENVIRONMENT 3.1. Natural occurrence 3.1.1. Rocks, soils, and sediments 3.1.2. Air 3.1.3. Water 3.1.4. Biota 3.2. Industrial production and uses of arsenic 3.2.1. Industrial production 3.2.2. Uses of arsenic compounds 3.2.3. Sources of environmental pollution 4. ENVIRONMENTAL TRANSPORT AND DISTRIBUTION 4.1. General 4.2. Aquatic systems 4.3. Air-soil systems 5. LEVELS OF EXPOSURE TO ARSENIC AND ITS COMPOUNDS 5.1. General population exposure through air, drinking water, food, and beverages 5.1.1. Air 5.1.2. Drinking water 5.1.3. Food and beverages 5.1.4. Tobacco Page 2 of 149 Arsenic (EHC 18, 1981) 5.1.5. Drugs 5.1.6. Total daily intake in the general population 5.2. Occupational exposure 6. METABOLISM OF ARSENIC 6.1. Inorganic arsenic 6.1.1. Absorption 6.1.1.1 Respiratory deposition and absorption 6.1.1.1.1 Animals 6.1.1.1.2 Man 6.1.1.2 Gastrointestinal absorption 6.1.1.2.1 Animals 6.1.1.2.2 Man 6.1.1.3 Skin absorption 6.1.1.3.1 Animals 6.1.1.3.2 Man 6.1.1.4 Placental transfer 6.1.1.4.1 Animals 6.1.1.4.2 Man 6.1.2. Distribution in organisms 6.1.2.1 Fate of arsenic in blood 6.1.2.1.1 Animals 6.1.2.1.2 Man 6.1.2.2 Tissue distribution 6.1.2.2.1 Animals 6.1.2.2.2 Man 6.1.3. Elimination 6.1.3.1 Animals 6.1.3.2 Man 6.1.4. Biotransformation 6.1.4.1 Animals 6.1.4.2 Man 6.2. Organic arsenic compounds 6.2.1. Absorption 6.2.1.1 Respiratory absorption 6.2.1.1.1 Animals 6.2.1.1.2 Man 6.2.1.2 Gastrointestinal absorption 6.2.1.2.1 Animals 6.2.1.2.2 Man 6.2.1.3 Skin absorption 6.2.1.4 Placental transfer 6.2.1.4.1 Animals 6.2.1.4.2 Man 6.2.2. Distribution in organisms 6.2.2.1 Fate of organic arsenic in blood 6.2.2.1.1 Animals 6.2.2.1.2 Man 6.2.2.2 Tissue distribution of organic arsenic 6.2.2.2.1 Animals 6.2.2.2.2 Man 6.2.3. Elimination 6.2.3.1 Animals 6.2.3.2 Man 6.2.4. Biotransformation 6.2.4.1 Animals 6.2.4.2 Man 7. NORMAL LEVELS IN MAN AND BIOLOGICAL INDICATORS OF EXPOSURE 7.1. Blood 7.2. Urine Page 3 of 149 Arsenic (EHC 18, 1981) 7.3. Hair 7.4. Other tissues 8. EFFECTS AND DOSE-RESPONSE RELATIONSHIPS OF INORGANIC ARSENIC 8.1. Acute and subacute effects after short-term exposure 8.1.1. Man 8.1.2. Animals 8.2. Effects on reproduction and teratogenicity 8.2.1. Man 8.2.2. Animals 8.3. Noncarcinogenic effects after long-term exposure and sequelae of short-term exposure to inorganic arsenic 8.3.1. Effects on the respiratory system 8.3.1.1 Man 8.3.1.2 Animals 8.3.2. Effects on skin 8.3.2.1 Man 8.3.2.2 Animals 8.3.3. Effects on the liver 8.3.3.1 Man 8.3.3.2 Animals 8.3.4. Effects on the cardiovascular system 8.3.4.1 Man 8.3.4.2 Animals 8.3.5. Effects on the nervous system 8.3.5.1 Man 8.3.5.2 Animals 8.3.6. Effects on other organs 8.3.6.1 Man 8.3.6.2 Animals 8.4. Carcinogenicity 8.4.1. Man 8.4.1.1 Cancer of the respiratory system 8.4.1.2 Cancer of the skin 8.4.1.3 Cancer of the liver 8.4.1.4 Leukaemia and tumours of the haematopoietic system 8.4.1.5 Cancer of other organs 8.4.2. Experimental animal studies 8.4.2.1 Cancer of the respiratory system 8.4.2.2 Skin application 8.4.2.3 Oral administration 8.4.2.4 Other experimental systems 8.5. Mutagenicity 8.6. Mechanisms of toxicity 9. EFFECTS AND DOSE-RESPONSE RELATIONSHIPS OF ORGANIC ARSENIC COMPOUNDS 9.1. Acute and chronic toxicity 9.1.1. Man 9.1.2. Animals 9.2. Teratogenicity 9.3. Carcinogenicity 9.3.1. Animals 9.4. Mutagenicity 9.5. Mechanisms of toxicity 10. INTERACTIONS WITH OTHER CHEMICALS 10.1. Thiol-compounds 10.2. Selenium Page 4 of 149 Arsenic (EHC 18, 1981) 10.3. Cadmium and lead 11. EVALUATION OF HEALTH RISKS TO MAN FROM EXPOSURE TO ARSENIC 11.1. Introduction 11.2. Exposure 11.3. Inorganic arsenic compounds 11.3.1. Acute and subacute effects after short-term exposure 11.3.2. Noncarcinogenic effects after long-term exposure and sequelae of short-term exposure 11.3.2.1 Skin effects 11.3.2.2 Cardiovascular effects 11.3.2.3 Neurological effects 11.3.3. Carcinogenicity 11.3.3.1 Cancer of the respiratory system 11.3.3.2 Skin cancer 11.4. Organic arsenic compounds 11.5. Assessment of the cancer risk for man from exposure to inorganic arsenic REFERENCES NOTE TO READERS OF THE CRITERIA DOCUMENTS While every effort has been made to present information in the criteria documents as accurately as possible without unduly delaying their publication, mistakes might have occurred and are likely to occur in the future. In the interest of all users of the environmental health criteria documents, readers are kindly requested to communicate any errors found to the Division of Environmental Health, World Health Organization, Geneva, Switzerland, in order that they may be included in corrigenda which will appear in subsequent volumes. In addition, experts in any particular field dealt with in the criteria documents are kindly requested to make available to the WHO Secretariat any important published information that may have inadvertently been omitted and which may change the evaluation of health risks from exposure to the environmental agent under examination, so that the information may be considered in the event of updating and re-evaluation of the conclusions contained in the criteria documents. WHO TASK GROUP ON ENVIRONMENTAL HEALTH CRITERIA FOR ARSENIC Members Dr R. Albert, Institute of Environmental Medicine, New York University Medical Center, New York, NY, USA (Chairman of Subgroup 2) Dr V. Bencko, Department of General and Environmental Hygiene, Medical Faculty of Hygiene, Charles University, Prague, Czechoslovakia Dr G. Corey, Department of Environment Programs, Ministry of Health, Santiago, Chile Dr L.
Load more

Recommended publications
  • Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them
    Europaisches Patentamt European Patent Office © Publication number: 0046 270 A1 Office europeen des brevets ™ EUROPEAN PATENT APPLICATION @ Application number: 81106277.7 © Int. CI.3: C 07 C 103/78, C 07 C 93/26, C 07 C 69/24, C 07 C 1 53/07, @ Date of filing: 12.08.81 C07C 69/28 // C07C1 25/065 <§) Priority: 13.08.80 US 177825 © Applicant: INTERx RESEARCH CORPORATION, 2201 West 21 st Street, Lawrence Kansas 66044 (US) © I nventor : Bodor, Nicholas S., 31 5 Southwest 91 st Street, ® Dateofpublicationofapplication:24.02.82 S^^S^mHariMBM Bulletin m/b Terrace, Gainesville, Florida 32605 (US) Inventor: Pogany, Stefano A., 520 Louisiana Street, Lawrence Kansas 66044 (US) @ Designated Contracting States : AT BE CH DE FR GB IT ® Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Mori, LI LU NL SE Gritschneder P.O. Box 86 01 09, D-8000 Munchen 86 (DE) Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them. Novel@ Novel transient prodrug forms of bio-affecting phe- amyl, CH2ONO2,CH2ON02, -CH2OCOR2 or any non-heterocyclic nolic compounds are selected from the group consisting of member of the group defined by R2Rz above; and n.isn is at least those having the structural formula (I): one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol o etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): R2-C-X-CH-0- (I) I O R, II R2-C-X-CH-0- -RM-i-O-C-R2 (II) wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl;alky!;
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Arsenic in the Environment
    Durham E-Theses Arsenic in the environment Jones, Iwan E. LI. How to cite: Jones, Iwan E. LI. (1997) Arsenic in the environment, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/4730/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk ARSENIC IN THE ENVIRONMENT by Iwan E. LI. Jones A dissertation submitted to the University of Durham in fulfilment of the requirement for the degree of MSc by Research The copyright of this thesis rests with the author. No quotation from it should be published without the written consent of the author and information derived from it should be acknowledged. September 1997 5 MAR m ACKNOWLEDGEMENTS In the writing of this work, I must first thank Dr Stephen Thomas for the initial opportunity to study for a PhD. Since then, he has been a continued help in the search for funding in various shapes and forms, and although this work is not in his field of expertise, he has maintained a continued interest in its progress, and occasionally provided me with an opportunity to work back in the 'real world'.
    [Show full text]
  • Interaction Between Naturally Occurring Arsenic and Human Activities Harue Masuda
    Masuda Progress in Earth and Planetary Science (2018) 5:68 Progress in Earth and https://doi.org/10.1186/s40645-018-0224-3 Planetary Science REVIEW Open Access Arsenic cycling in the Earth’s crust and hydrosphere: interaction between naturally occurring arsenic and human activities Harue Masuda Abstract Field-based research on naturally occurring arsenic contamination of surface waters and groundwaters and the mechanisms of contamination are reviewed. The distribution of arsenic is strongly related to areas of active plate tectonics, magmatism and associated hydrothermal activity, and high rates of erosion. Sources of arsenic contamination are mainly hydrothermal water, sulfide and arsenide minerals, volcanic ash, and iron oxyhydroxide/oxide as weathering products. The promotion of the reduction and oxidation of arsenic source minerals by in situ microbial activity is an important secondary mechanism that often determines arsenic levels in groundwater. Anthropogenic activities, such as geothermal and mining operations, as well as excess pumping of shallow groundwaters, disperse arsenic in the environment, thereby expanding areas of arsenic contamination. Keywords: Arsenic contamination, Geologic cycle, Plate tectonics, Reduction, Oxidation Introduction country: Japan (since 1993), the USA, Canada (both since Human beings are facing a crisis of an increasing demand 2006; EPA 2018;HealthCanada2017), and Australia for freshwater in the face of decreasing freshwater re- (since 2011; NHMRC and NRMMC 2011)followthe sources. One of the most serious problems threatening WHO guideline of 10 μg/L, but many developing coun- water resources is contamination with arsenic, which is tries still apply the older standard of 50 μg/L. highly toxic. Since the late 1980s, when the arsenicosis Arsenic is a minor but ubiquitous element of the Earth’s was reported in West Bengal, India (Mandal and Suzuki crust, and some chemical species of this amphoteric elem- 2002), arsenic-contaminated groundwater and associated ent are volatile and highly soluble in aquatic solution.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Alfa Laval Black and Grey List, Rev 14.Pdf 2021-02-17 1678 Kb
    Alfa Laval Group Black and Grey List M-0710-075E (Revision 14) Black and Grey list – Chemical substances which are subject to restrictions First edition date. 2007-10-29 Revision date 2021-02-10 1. Introduction The Alfa Laval Black and Grey List is divided into three different categories: Banned, Restricted and Substances of Concern. It provides information about restrictions on the use of Chemical substances in Alfa Laval Group’s production processes, materials and parts of our products as well as packaging. Unless stated otherwise, the restrictions on a substance in this list affect the use of the substance in pure form, mixtures and purchased articles. - Banned substances are substances which are prohibited1. - Restricted substances are prohibited in certain applications relevant to the Alfa Laval group. A restricted substance may be used if the application is unmistakably outside the scope of the legislation in question. - Substances of Concern are substances of which the use shall be monitored. This includes substances currently being evaluated for regulations applicable to the Banned or Restricted categories, or substances with legal demands for monitoring. Product owners shall be aware of the risks associated with the continued use of a Substance of Concern. 2. Legislation in the Black and Grey List Alfa Laval Group’s Black and Grey list is based on EU legislations and global agreements. The black and grey list does not correspond to national laws. For more information about chemical regulation please visit: • REACH Candidate list, Substances of Very High Concern (SVHC) • REACH Authorisation list, SVHCs subject to authorization • Protocol on persistent organic pollutants (POPs) o Aarhus protocol o Stockholm convention • Euratom • IMO adopted 2015 GUIDELINES FOR THE DEVELOPMENT OF THE INVENTORY OF HAZARDOUS MATERIALS” (MEPC 269 (68)) • The Hong Kong Convention • Conflict minerals: Dodd-Frank Act 1 Prohibited to use, or put on the market, regardless of application.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Risk Assessment Report Arsenic in Foods (Chemicals and Contaminants)
    [Tentative translation] Risk Assessment Report Arsenic in foods (Chemicals and Contaminants) Food Safety Commission Japan (FSCJ) October 2013 0 [Tentative translation] Contents Page Chronology of Discussions .................................................................................................... 3 List of members of the Food Safety Commission .................................................................. 3 List of members of the EPCC, the Food Safety Commission ................................................ 4 Executive summary ................................................................................................................ 6 I. Background ......................................................................................................................... 9 II. Outline of the Substances under Assessment .................................................................... 9 1. Physiochemical properties ......................................................................................... 9 (1) Metallic arsenic ................................................................................................... 9 (2) Inorganic arsenic compounds ........................................................................... 10 (3) Organic arsenic compounds .............................................................................. 12 (4) Analytical methods for arsenic ......................................................................... 16 2. Major use and production .......................................................................................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/033635 Al 10 March 2016 (10.03.2016) P O P C T (51) International Patent Classification: AN, Martine; Epichem Pty Ltd, Murdoch University Cam Λ 61Κ 31/155 (2006.01) C07D 249/14 (2006.01) pus, 70 South Street, Murdoch, Western Australia 6150 A61K 31/4045 (2006.01) C07D 407/12 (2006.01) (AU). ABRAHAM, Rebecca; School of Animal and A61K 31/4192 (2006.01) C07D 403/12 (2006.01) Veterinary Science, The University of Adelaide, Adelaide, A61K 31/341 (2006.01) C07D 409/12 (2006.01) South Australia 5005 (AU). A61K 31/381 (2006.01) C07D 401/12 (2006.01) (74) Agent: WRAYS; Groud Floor, 56 Ord Street, West Perth, A61K 31/498 (2006.01) C07D 241/20 (2006.01) Western Australia 6005 (AU). A61K 31/44 (2006.01) C07C 211/27 (2006.01) A61K 31/137 (2006.01) C07C 275/68 (2006.01) (81) Designated States (unless otherwise indicated, for every C07C 279/02 (2006.01) C07C 251/24 (2006.01) kind of national protection available): AE, AG, AL, AM, C07C 241/04 (2006.01) A61P 33/02 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07C 281/08 (2006.01) A61P 33/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07C 337/08 (2006.01) A61P 33/06 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07C 281/18 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/AU20 15/000527 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 28 August 2015 (28.08.2015) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]